spacer
home > ict > Spring 2011
PUBLICATIONS

International Clinical Trials

ict
Spring 2011

   
Text
PDF
bullet
REGULATORY

Along with recent legislation, Alexander Cvetkovich-Muntañola and Kathryn Bohannon of INC Research look at the factors to consider when designing a paediatric protocol, highlighting that the many complications associated with clinical trials in children mean that sponsors should commit sufficient time to formulating a strategy before initiating such studies.


 
view
download pdf
Consultant Stephen A Goldman examines current perspectives and approaches to pharmacovigilance planning and risk management throughout the medical product life cycle, from clinical trials through product approval to marketing.
 
view
download pdf
Since the enforcement of the Paediatric Regulation in 2007, sponsors must now complete a paediatric investigation plan (PIP) when seeking marketing approval for unauthorised drugs or new indications. Douglas Fiebig at Trilogy Writing & Consulting puts forward the six main steps when preparing a PIP application.
 
view
download pdf
bullet
Regional trials
Clinical research in Central and South American countries and the Caribbean is by no means a new phenomenon, but recent regulatory changes and political developments have caught the headlines.Maria Alejandra Espinosa and Ivana Etcheverry at Omnicare Clinical Research reacquaint us with the region, giving a breakdown of the changes by country.
 
view
download pdf
eCLINICAL, DATA MANAGEMENT & STATISTICAL ANALYSIS
As the clinical research associate’s role evolves to take a more hands-on approach to site management, Liz Love of Perceptive Informatics examines how eClinical solutions and clinical trial management systems will help them make their decisions easier.
 
view
download pdf
Linda Bowers of IntraLinks discusses how software-as-a-service based solutions can be used to strengthen the relationship between investigators, as well as build various strategic partnership models between sponsors and CROs.
 
view
download pdf
bullet
THERAPEUTICS
Douglas W Loe of Versant Partners discusses the potential of using oncolytic viruses as a form of cancer treatment, giving an update of viruses in various stages of development for a range of cancers, as well as some indicators of potential future sales earnings that can be derived from these treatments.
 
view
download pdf
bullet
Labs & Logistics

Data management for the pharmaceutical cold chain is a considerable challenge. Martin Peter at ELPRO-BUCHS AG Switzerland investigates the different techniques on offer for collecting this essential data, as well as how to overcome the challenges it may create.


 
view
download pdf

Russ Hager of BioStorage Technologies highlights the growing role of cold chain management in supply chain processes, and emphasises the various factors that ensure on-time, compliant transportation of temperature-sensitive clinical trial materials and supplies.

 

 
view
download pdf
bulletMetrics Champion Consortium

In spite of how ‘old’ the pharma industry is, there is still a lack of industry-adopted clinical trial performance metrics.However,well-defined standards are needed to provide the fundamental tools for running efficient, effective clinical trials, explains Linda Buchin Sullivan of the Metrics Champion Consortium (MCC).


 
view
download pdf
Nick Jackson at i3 presents both a customer’s and a CRO’s perspective on using the MCC metrics, and discusses the role of the Process Improvement Work Group.
 
view
download pdf

Business Practice
Like any other business, pharmaceuticals need performance indicators to measure business success, but unlike any other business, the industry has a unique model. So, how do you pilot a business that is like no other? Dimitri Stamatiadis at Merck Serono suggests that a balanced scorecard might be the answer.
 
view
download pdf

Company stakeholders frequently view quality assurance as a ‘nice to have’, and are not always aware of its full impact on the organisation if it is not taken seriously. Nicky Dodsworth and Sherri Hubby at Premier Research Group Ltd stress that in the struggle for survival in today’s regulatory environment, quality assurance must take a more active role.

 
view
download pdf
As with every other aspect of life, clinical research companies must ensure they have appropriate insurance for their activities.However, they cannot afford for this protection to hinder speed-to-market efforts. As a result, there is a need for web-based technologies to make the process more efficient and transparent, explains Kathleen Burns of Aon eSolutions.
 
view
download pdf

Training & Development
For an industry boasting excellence and the use of cutting-edge technology in all aspects of its operation, the pharma world is only just beginning to regard the role clinical events with the same importance as other parts of a study. Andy Thurstan at MD Events considers best practices for planning and delivering outstanding meetings.
 
view
download pdf
It is vital that clinical research organisations have well-trained employees who are equipped to operate at the highest standard.Gerald Van Roey at the European Centre for Clinical Research Training gives some tips for designing a strong staff development programme.
 
view
download pdf
Many organisations are trying to find ways to cut their budgets, and often one of the first casualties is training. However, developing a strong coaching culture in an organisation can prove to be a cost-effective measure in the long term, explains Martin Robinson of Dovetail Clinical.
 
view
download pdf
   
spacer
Edited by
Dr Graham Hughes
Consultant in
Pharmaceutical
Development

Published quarterly in
February, May,
August, and November

News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement